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Neonatal systemic candidiasis is increasingly being recog-
nized as a cause of septicemia in the neonatal intensive care
unit (2, 19, 26, 36, 59). Predisposing factors for candidemia and
subsequently invasive infections include prematurity, pro-
longed exposure to broad-spectrum antibiotics, the use of in-
travenous fat emulsions, the presence of necrotizing enteroco-
litis, prolonged intravascular catheterization, and tracheal
intubation (33, 49, 50, 51, 63). Moreover, the immune func-
tions of the newborn, especially in the preterm infant, are
suboptimal, manifested as a decreased T-cell and granulocyte
function (6, 22, 65). Additionally, it has been shown that lung
macrophages of newborns have reduced anti-Candida activity
(16). Infection is preceded generally by colonization of the
gastrointestinal tract and the skin shortly after delivery (1, 27).
Clinical evidence suggests that heavy colonization at multiple
sites is a predisposing factor for clinical disease (27, 41), al-
though this is still controversial (40). Most fungal infections in
newborns are caused by Candida albicans, Candida parapsilo-
sis, and more rarely, Candida tropicalis (1, 20, 42, 48).
The symptoms of systemic candidal infection in the newborn
are not specific. In several studies deterioration of respiratory
function and apnea were the most common presenting signs,
occurring in 70% of infants (2, 10, 26). Temperature instability,
irritability, abdominal distension, carbohydrate intolerance,
rash, and lethargy were also commonly observed. Similar
symptoms are noted in newborns with bacterial infections,
which occur frequently or coincidentally with systemic candi-
diasis. Therefore, most fungemic newborns are presumptively
treated for bacterial infection. Since the signs, symptoms, and
results of hematologic studies for infants suspected of having
candidiasis are not specific, positive cultures are the mainstay
in the diagnosis of invasive candidiasis. However, in newborn
patients most antifungal therapy is started when fungal ele-
ments are seen on Gram stain or yeasts are isolated from some
body fluid. On occasion it is even begun empirically or on the
basis of the presence of a suggestive rash. Amphotericin B with
or without flucytosine is still the treatment of choice for new-
borns with systemic candidiasis. However, since the introduc-
tion of ketoconazole in 1981, fluconazole in 1990, and intra-
conazole in 1992, these antifungal azoles, which unlike
amphotericin B can be given orally, there has been a tendency
to use these drugs as alternative therapies. Physicians have
been influenced by the efficacy, safety, and ease of the admin-
istration of the azoles, despite the lack of direct comparisons of
the efficacies of these drugs and amphotericin B. Our purpose
here is to present an overview of the available pharmacokinetic
data for amphotericin B, flucytosine, and this new group of
azole drugs in the newborn. Dosage recommendations, recom-
mendations for dosage adjustments in the face of organ system
failure, and recommendations for monitoring toxicity will be
suggested.
AMPHOTERICIN B
The antifungal activity of amphotericin B is related to its
binding with ergosterol and other sterols of the fungal cell
membrane which produces a disruption of its integrity and
transport characteristics in susceptible organisms, resulting in
the loss of intracellular potassium (3, 32). Resistance can de-
velop very slowly and may result from a decrease in the con-
centration of ergosterol in the fungal cell membrane (32).
In 1984 Baley et al. (2) reported that 7 of 10 infants receiving
amphotericin B for systemic fungal infections had severe neph-
rotoxicity with oliguria or anuria and marked increases in
blood urea nitrogen and creatinine. However, several infants
had confounding factors such as prior poor renal function and
multiple drug therapies. The nephrotoxicity was seen in one
infant after administration of the first 0.25 mg/kg of body
weight, whereas the others required an average cumulative
dose of 6.5 mg/kg before renal side effects occurred. The
deaths of six of these infants were attributed, in part, to am-
photericin B-induced nephrotoxicity. Since that report, the
pharmacokinetics of amphotericin B in newborns have been
studied and most of the treated infants have had more favor-
able outcomes. In contrast to adults, who experience fever,
chills, nausea, and vomiting, infants tolerate infusion well (18,
26, 45, 62). The major side effects are transient nephrotoxicity,
hepatotoxicity, and bone marrow suppression. Amphotericin B
specifically suppresses production of erythrocytes because of
inhibition of erythropoietin production (35). In infants and
children it has been shown that after 1 week of treatment the
creatinine level rose but reverted to the baseline level by the
end of treatment (54). There have also been reports of inad-
vertent overdosing of infants (29, 38). Koren et al. (29) de-
scribed an infant who received 50 times the normal dose of
amphotericin B on three separate occasions. Except for a mild
persistent elevation of g-glutaryltransferase levels, the infant
tolerated the massive overdose without any other measurable
difficulty and remained well later on. There appears to be a
high degree of variability in peak levels in serum, elimination
half-life in serum and volume of distribution of amphotericin B
among infants (Table 1) (3, 54, 62). The data from different
investigators cannot easily be compared because of different
dosing schedules and assays of drug concentrations. Most stud-
ies document a longer elimination half-life in serum in smaller
infants, who appeared to accumulate the drug. Koren et al.
(30) speculated that maturation of the hepatic metabolism of
amphotericin B takes place in infancy and childhood. The
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practical implication of the age-dependent changes in the half-
life in serum is that it may take significantly longer periods to
achieve steady state in the younger infant (30).
In contrast to adults, in whom the concentrations of ampho-
tericin B in cerebrospinal fluid may be only 2 to 4% of those in
serum (43), in five infants in whom concentrations of ampho-
tericin B in cerebrospinal fluid were studied, the levels were 40
to 90% of those in serum (3). This may explain why infants with
fungal meningitis have similar outcomes whether they are
treated with amphotericin B alone or with flucytosine. Assays
of amphotericin B in joint fluid also revealed concentrations
similar to those in serum (54). Urinary excretion is less than
5% of the concentration in serum (66). Therapeutic dosing of
amphotericin B is started at 0.25 mg/kg. This is usually fol-
lowed by daily increases of 0.25 mg/kg to achieve a daily dose
of from 0.5 to 1.0 mg/kg. For patients with severe disease, dose
increases have been used every 12 h, and these have been well
tolerated. Although 0.5 mg/kg may be efficacious (2, 3, 26),
daily doses of up to 1.5 mg/kg have been safely given (10). The
optimal dose and duration of amphotericin B therapy for sys-
temic candidiasis in adults are unknown, although the drug has
been available for more than 30 years. Also, in infants and
children the proposed duration of therapy is rather variable.
Sa´nchez et al. (45) advise a total dose of 10 to 20 mg of
amphotericin B per kg for most infants with uncomplicated
catheter-associated candidemia, whereas Butler et al. (11) rec-
ommend a minimum total dose of 25 mg/kg in infants with
disseminated candidal disease. At present, therapy should
therefore be individualized on the basis of the type of infection,
the immune functions of the newborn, and the newborn’s re-
sponse while on therapy. Careful monitoring of renal function,
blood counts, and electrolytes is required, and adjustments to
the drug dose and the dosing interval are based on studies of
those parameters.
An interesting new development for the near future is the
administration of amphotericin B in lipid complexes or lipo-
somes. The incorporation of amphotericin B in liposomes re-
sulted in decreased toxicity and enhanced therapeutic efficacy
against several infections in animals (37). The role of liposomal
amphotericin B in the newborn has still to be elucidated (31).
FLUCYTOSINE
Flucytosine is a fluorine analog of cytosine, a normal body
constituent. After deamination in the fungal cell, the drug is
transformed to 5-fluorouracil, which acts as an inactive pyrim-
idine substitute and which also inhibits thymidylate synthetase.
These two mechanisms interfere with DNA synthesis and cell
growth (32). The development of secondary resistance has
been demonstrated in vitro and can occur during therapy,
especially when the drug is used on its own (2, 14, 32). Flucy-
tosine is used as adjunctive therapy with amphotericin B, al-
though the need for it has recently been debated (11). At
present there are few clinical data on the efficacy of flucytosine
alone or in combination with amphotericin B for the treatment
of neonatal systemic candidiasis. Furthermore, the use of flucy-
tosine, which is available only for oral administration, is limited
because preterm infants are often unable to tolerate oral med-
ications.
Side effects occur in about 5% of adult patients and gener-
ally involve the bone marrow, liver, and gastrointestinal tract.
Gastrointestinal and hepatic toxicities apparently are not re-
lated to the concentrations of flucytosine in serum, whereas
myelosuppression does correlate with the concentrations in
serum. The most common gastrointestinal toxicities are nau-
sea, vomiting, and diarrhea. Hepatic toxicities consist of ele-
vated transaminase and alkaline phosphatase levels in serum,
which are reversible. Rarely, patients develop patchy hepatic
necrosis. Flucytosine toxicity occurred in 62% of 37 patients in
whom the concentrations of drug in serum were .100 mg/liter
for 2 or more weeks but in only 31% of 48 patients in whom the
concentrations in serum were ,100 mg/liter (53). Myelosup-
pression is the toxicity of the greatest concern and may be
manifested as anemia, leukopenia, and thrombocytopenia.
Presumably, this toxicity is due to the conversion of flucytosine
to 5-fluorouracil in the gastrointestinal tract. If the concentra-
tion of flucytosine in serum exceeds 100 mg/liter, the concen-
tration of 5-fluorouracil in serum likely exceeds 1 mg/liter,
which is within its therapeutic range (17). The hematological
side effects have been related to concentrations of flucytosine
in serum of greater than 100 mg/liter (28). Flucytosine is not
directly nephrotoxic, although approximately 90% of the drug
is excreted unchanged in the urine of adults. The elimination
rate constant is directly related to glomerular filtration, so that
potentially dangerous levels may occur if glomerular filtration
is impaired (62). Several studies did not show any side effects
of flucytosine in infants (12, 18, 26, 62). Baley et al. (3) re-
ported that in two of seven autopsied infants, hepatic necrosis
was present.
There appears to be a high degree of variability in peak
levels in serum, elimination half-life in serum, and volume of
distribution of flucytosine among the studied infants (Table 2)
(3, 26, 50, 62). The data from different investigators cannot
easily be compared because of different dosing schedules, dif-
ferent assays of drug concentrations, and both parenteral or
enteral administration of flucytosine. Moreover, only one study
provided us with the full pharmacokinetic parameters of flucy-
tosine (3). Baley et al. (3) showed that the elimination half-
lives in the sera of 12 infants were variable, ranging from 3.4 to
34.1 h, with a median of 7.5 h, which is twice that in the sera of
adults (13). The penetration of flucytosine into the cerebrospi-
nal fluid of newborns is excellent (Table 3) (26, 50).
As with amphotericin B, the optimal dose and duration of
treatment with flucytosine are unknown. In the reports re-
viewed here, the dosage has ranged from 50 to 200 mg/kg/24 h,
and the duration of treatment has ranged from 10 to 120 days.
Baley et al. (3) recommend a dosing interval of 24 h in new-
borns rather than the 6-h interval recommended for adults,
because they showed that the median half-life of flucytosine in
the newborns studied was prolonged compared with the half-
life found in adults (3).
TABLE 1. Pharmacokinetics of AmBa
Reference Dosage(mg/kg/24 h)
Dose
(mg/kg)
Peak level
(mg/liter)
Trough level
(mg/liter)
Half-life
(h)
Vol. of distribution
(liters/kg)
Clearance
(ml/min/1.73 m2)
Clearance
(ml/min/kg)
Baley et al. (2) 0.5 0.96 (0.5–4.0) 14.8 (5–82) 1.5 (0.1–17.5) 18.0 (7.7–72.3)
Starke et al. (54) 1.0 0.31–1.22 0.08–0.32 7.46–62.5 1.5–5.4 0.78–3.87
Ward et al. (62) 0.5–1.0 0.20–0.65 0.20
a Values are expressed as mean (range).
1392 MINIREVIEW ANTIMICROB. AGENTS CHEMOTHER.
Careful monitoring of transaminase and alkaline phos-
phatase levels in serum, renal function, and blood counts is
required, and adjustments to the drug dose and the dosing
interval are based on studies of these parameters. Additionally,
because the hematological side effects have been associated
with concentrations of flucytosine in serum greater than 100
mg/liter, monitoring of flucytosine levels is indicated to appro-
priately adjust the dosing schedule.
KETOCONAZOLE
Ketoconazole is an imidazole derivative. The antifungal ac-
tivity of ketoconazole is related to its inhibition of 14-a-de-
methylation of lanosterol by binding to one of the cytochrome
enzymes. This impairs the synthesis of ergosterol and inter-
feres with the formation of other cell membrane lipids (32).
The development of clinically important resistance to ketocon-
azole, even after prolonged courses of therapy, is unknown.
The use of ketoconazole, which is available only for oral
administration, is limited because preterm infants are often
unable to tolerate oral medications. Furthermore, ketocon-
azole is a weak base and requires an acid environment for
optimal solubilization and absorption. Side effects occur in
about 2 to 10% of adult patients and generally involve the liver
and the gastrointestinal tract. Although most patients with
ketoconazole-induced elevations in aminotransferase concen-
trations in plasma are asymptomatic, ketoconazole may cause
clinically important and even fatal hepatitis (34). Moreover,
ketoconazole may reversibly inhibit the synthesis of testoster-
one (and therefore estradiol) and cortisol, resulting in a variety
of endocrine disturbances, including gynecomastia, oligosper-
mia, loss of libido, impotence, menstrual irregularities, and
very rarely, adrenal insufficiency (44, 52). Most side effects are
dose related. Side effects in newborns have not been reported.
The data from different investigators cannot easily be com-
pared because of the different ages, different dosing schedules,
and different assays of drug concentrations and the use of
solutions, tablets, and crushed tablets (Table 4) (4, 57). Bar-
dare et al. (4) reported the pharmacokinetics of ketoconazole
treatment in 26 children (ages, 5 months to 14 years). Keto-
conazole was given as a suspension or as tablets. Double peaks
were observed in two patients receiving ketoconazole tablets,
probably because of enterohepatic circulation or delayed ab-
sorption. In a study by Ginsburg et al. (23) a comparison
between the pharmacokinetics of ketoconazole after adminis-
tration as a commercially prepared suspension or as a crushed
tablet in applesauce in 12 children from 2 to 12.5 years of age
was made (23). The mean peak concentration of ketoconazole
in plasma and areas under the serum concentration-time
curves were approximately twofold higher for those receiving
the suspension than for those receiving the powder. They
found a considerable variation in concentrations in plasma.
The half-life in plasma tended to be longer after administra-
tion of crushed tablets than after administration of the suspen-
sion; however, this difference was not significant. Of the pa-
tients receiving the suspension, peak concentrations in plasma
were 4 mg/ml or greater in 67% of them.
In the study of Bardare et al. (4), 26 children with candidiasis
were treated with ketoconazole. A total of 73% of the children
were cured and 11.5% improved. Failure was observed in one
patient who was being treated with cimetidine at the same time
(4). Van den Anker et al. (58) showed that with dosages of 3
and 6 mg of ketoconazole per kg/day given orally as a single
drug to preterm infants, measurable concentrations in serum
were not reached. They suggested that a possible explanation is
that absorption of ketoconazole is prevented by a combination
of low or absent gastric acid secretion, continuous gavage feed-
ing, and the high buffering capacity of milk. In a supplementary
study of van den Anker et al. (57) the relation between gastric
pH and the bioavailability of ketoconazole was studied with
eight preterm infants who received a single oral dose of 10 mg
of ketoconazole per kg. In seven of the eight infants, appro-
priate absorption of ketoconazole was demonstrated. The con-
clusion of that study was that ketoconazole is absorbed (pH
dependent) from the gastrointestinal tract in preterm infants.
Bardare et al. (4) concluded that a dosage of at least 8 mg/kg/
day is needed to achieve acceptable concentrations in serum
and definite cures, although Bardare et al. (4) gave ketocon-
azole as a suspension. They found, however, that the same
dosage was suitable for children receiving tablets, provided
TABLE 2. Pharmacokinetics of flucytosinea
Reference Dosages(mg/kg/24 h)
Dose
(mg/kg)
Peak level
(mg/liter)
Trough level
(mg/liter)
Concn in serum
at steady state
(mg/liter)
Half-life
(h)
Vol of distribution
at steady state
(liters/kg)
Clearance
(ml/min/1.73 m2)
Clearance
(ml/min/kg)
Ward et al. (62) 40 25 8
80 37 27
Johnson et al. (26) 25 576 10 1.2
Smith and Congdon (50) 100–200 50–100 25–100
25 19.6
Baley et al. (2) 50 27.7 (11–44) 7.4 (3.4–34.1) 1.1 (0.1–2.0) 34.2 (8.72–49.2)
100 83.9
a Values are expressed as median (range).
TABLE 3. Drug concentrations in cerebrospinal fluid
Reference Druga Dosage(mg/kg/24 h)
Concn
( mg/liter)
Baley et al. (2) AmB 0.5 —b
Johnson et al. (26) 5FC 25 43
Smith and Congdon (50) 5FC 120–150 20–67
Bardare et al. (4) KCZ NDc–0.03
Cruciani et al. (15) FLU 6 6.6–8.6
a AmB, amphotericin B; 5FC, flucytosine; KCZ, ketoconazole; FLU, flucon-
azole.
b—, the concentration was determined to be 40 to 90% of the concentration
in serum.
c ND, not detectable.
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that an antacid drug was not administered simultaneously (4).
There is no penetration of ketoconazole into the cerebrospinal
fluid of infants aged between 5 months and 14 years (4). Data
on the concentration of ketoconazole in the cerebrospinal fluid
of newborn infants are completely lacking.
The optimal dose and duration of treatment with ketocon-
azole are unknown. Because of the pH-dependent absorption
of ketoconazole, a low gastric pH must be guaranteed if keto-
conazole is used. Derived from the reviewed literature, a start-
ing dose of 8 to 10 mg of ketoconazole per kg would therefore
be appropriate. Because little ketoconazole is excreted in the
urine, the doses need not be changed in patients with renal
impairment.
Careful monitoring of aminotransferase concentrations in
plasma is obligatory. Therapy with ketoconazole should always
be discontinued for infants who have symptomatic hepatitis or
laboratory evidence of progressive or persistent hepatic dys-
function. Changes in steroidogenesis should be searched for.
FLUCONAZOLE
Fluconazole is a bistriazole antifungal agent. The mecha-
nism of action of fluconazole is by inhibition of fungal ergo-
sterol synthesis.
Until recently, the development of clinically important re-
sistance to fluconazole was rare (21, 39). However, treatment
failures are increasing among patients infected with the human
immunodeficiency virus who are receiving intermittent or con-
tinuous fluconazole therapy (46). Fluconazole is available as
both an oral and an intravenous formulation. The absorption
of oral fluconazole is not altered by the presence of food or
gastric acidity.
Side effects occur in about 1 to 7% of adult patients and
generally involve the liver and the gastrointestinal tract.
Asymptomatic elevations of aminotransferase levels in plasma
and hepatitis (rare) are seen (24). No effects of fluconazole on
steroidogenesis have been reported. Until now side effects in
newborn infants were not reported (9).
The pharmacokinetics of fluconazole were determined by
Saxen et al. (47) (Table 5), who treated 12 preterm infants
prophylactically with fluconazole in an attempt to eradicate a
C. parapsilosis outbreak on their neonatal intensive care unit.
Up to five doses of 6 mg of fluconazole per kg were adminis-
tered intravenously every 72 h during the first 2 weeks of life.
A remarkable finding was the doubling of the mean total clear-
ance corrected for body weight between dose 1 and dose 3 and
a further increase by approximately 58% between dose 3 and
dose 5. The clearance increased with postnatal age, whether or
not it was corrected for body weight, but not with postconcep-
tional age. This is probably an expression not only of renal
functional development but also of clinical improvement. The
other pharmacokinetic variables did not correlate with postna-
tal or postconceptional age. Wiest et al. (64) report a case of
systemic candidiasis in a preterm infant who was treated with
fluconazole after treatment with amphotericin B and flucy-
tosine failed. They determined the concentrations of flucon-
azole in serum and used a first-order, one-compartment model
to determine the pharmacokinetic parameters for fluconazole.
These parameters indicate a larger apparent volume of distri-
bution and a longer half-life compared with those in adults,
which was also found by Saxen et al. (47). According to Berg-
man et al. (7), the concentrations of fluconazole in plasma
after oral administration are sufficient. However, we like to
stress that we need carefully designed pharmacokinetic and
pharmacodynamic studies with newborn infants before we can
conclude that certain concentrations in serum are sufficient.
In an evaluation of fluconazole in the treatment of candidi-
asis in 24 immunocompromised children (median age, 6 years;
TABLE 4. Pharmacokinetics of ketoconazole
Reference
(dosage formulation)
Dose
(mg/kg)
Peak level
(mg/liter)
Concn in serum (mg/liter) at: Half-life
(h)
AUC (mg z h/ml) ata:
8 h 12 h 24 h 0–8 h 0–12 h 0–24 h
Bardare et al. (4)
Suspension 3 0.5 NDb 0.75 1.15
10 2.04 0.64 3.78 9.51
Tablets
One daily dose 8.70 6.30 1.81 0.72 0.04 2.38 36.67 40.67
Two daily doses 9.61 3.46 0.35 0.10 2.57 13.64
Van den Anker et al. (57) 10 1.41 8.80
a AUC, area under the concentration-time curve.
b ND, not detectable.
TABLE 5. Pharmacokinetics of fluconazole
Reference Dosage(mg/kg/24 h)
Dose
(mg/kg)
Peak level
(mg/liter)
Trough level
(mg/liter)
Half-life
(h)
Vol. of distribution
(liters/kg)
Clearance
(ml/min/kg)
Wiest et al. (64) 6 10.30 6.98 37.4 1.2 0.33
Bergman et al. (7) 20 11.1 6.8
Saxen et al. (47)
Dose 1 6 5.5 2.6 88.6 1.18 0.18
Dose 3 6 12.8 4.3 67.5 1.84 0.33
Dose 5 6 10.0 2.9 55.2 2.25 0.52
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age range, 13 days to 14 years), only 2 patients treated with the
standard dosages developed mild hepatotoxicity (61). Viscoli
et al. (61) demonstrated that a total of 34 treatment courses in
24 patients resulted in 30 clinical and microbiological cures
(88%). Four episodes (12%) did not respond to treatment, and
improvement was obtained with amphotericin B in one patient
in combination with flucytosine. Relapse occurred in 10 of the
30 responding episodes (33%) after the discontinuation of
treatment. Relapses were due to persistence of the predispos-
ing conditions. In the other articles reviewed here, treatment
with fluconazole was successful (7, 9, 15, 60, 64). The concen-
trations of fluconazole in cerebrospinal fluid were determined
by Cruciani et al. (Table 3) (15). When fluconazole is used in
the treatment of systemic candidiasis in neonates, it is admin-
istered at a dosage of 5 or 6 mg/kg/day either orally or intra-
venously (7, 9, 15, 60, 64). The length of treatment ranges from
8 days to 3 months. Saxen et al. (47) used a dosing schedule of
6 mg/kg every 3 days, which resulted in the presumed desired
mean trough concentrations of fluconazole in serum during the
first week of life. However, the resulting decrease in half-life
and trough concentrations in serum during the second week of
life, when the same dosage was continued, led them to suggest
that fluconazole should be administered every 2 days after the
first week of life. Their experience obtained after the study
period with the use of 6 mg of fluconazole per kg daily for 26
very low birth weight infants suggests that even higher doses of
fluconazole can be used. Because approximately 80% of an
administered dose of fluconazole is excreted unchanged in the
urine, the dose should be reduced in patients with an impaired
glomerular filtration rate. Careful monitoring of aminotrans-
ferase levels in plasma is indicated.
ITRACONAZOLE
Itraconazole is a triazole derivative. The mechanisms of ac-
tion are basically similar to those of the other azoles. It inhibits
the synthesis of ergosterol, and its use results in the simulta-
neous accumulation of 14-a-methysterols. Its effect seems to
be acquired principally through inhibition of the cytochrome
P-450 system (32). The development of clinically important
resistance to itraconazole is unknown. The use of itraconazole,
available only for oral administration, is limited because pre-
term infants are often unable to tolerate oral medications.
Furthermore, itraconazole is a weak base and requires an acid
environment for optimal solubilization and absorption. The
bioavailability of itraconazole is two to three times higher when
it is taken with food than when it is taken on an empty stomach
(5). The bioavailability of itraconazole is increased when it is
administered in hydroxypropyl-b-cyclodextrin, a cyclic oligo-
saccharide carrier molecule that increases the solubility of li-
pophilic compounds in aqueous solutions (25).
Side effects occur in about 1 to 5% of adult patients and
generally involve the liver and gastrointestinal tract. Asymp-
tomatic elevations of aminotransferase levels in plasma and
hepatitis (rare) are seen. No effects on steroidogenesis have
been reported. Side effects in newborn infants have not been
reported.
There is only one report of itraconazole levels in sera of
preterm neonates (56). Trough and peak levels of itraconazole
in serum were measured in six preterm neonates 48 h after
initiating therapy with itraconazole at 5 mg/kg/24 h and were
found to be 2766 41 and 856 18 mg/liter, respectively. A total
of five doses were administered. The area under the serum
concentration-time curve from 0 to 24 h could be determined
in four neonates and was found to be 5.1386 1.188 mg z h/liter.
Two reports (8, 55) describe three preterm infants with dis-
seminated candidiasis who were treated with itraconazole. All
three infants made a complete recovery (8, 55). In two studies
(54, 55) a dosage of 5 mg/kg/24 h was given orally. One study
showed that itraconazole given at 5 mg/kg/24 h is well absorbed
and that the recommended levels are reached in preterm ne-
onates of less than 32 weeks of gestational age (56). In the
other study a dosage of 10 mg/kg/day given orally was used in
both children (8). Treatment was given for 3 to 4 weeks (8, 55).
Because little itraconazole is excreted in the urine, the doses
need not be changed for patients with renal impairment. Care-
ful monitoring of aminotransferase levels in plasma is indi-
cated.
PERSPECTIVE
A more rapid and precise diagnosis of neonatal systemic
candidiasis and an optimal individualized treatment strategy
for the newborn with invasive candidiasis are major challenges
for clinicians and researchers in the field. The use of nucleotide
probes specific for Candida species and DNA amplification
procedures such as PCR probably will allow a rapid and precise
diagnosis of neonatal systemic candidiasis in the near future.
Determination of which drug should be used to treat an infec-
tion with a specific pathogen in a specific newborn still awaits
a lot of research. At present in vitro susceptibility testing of
antifungal agents against fungal organisms is of questionable
value because of the limited correlation of the results with the
clinical response. Moreover, comparisons of MICs from labo-
ratory to laboratory and from study to study should be inter-
preted with caution because the results are influenced by a
variety of factors, including the growth medium, pH, temper-
ature, and size of the inoculum. Because of the lack of stan-
dardized in vitro test systems, susceptibility testing of fungal
isolates against antifungal drugs should not be done routinely
in clinical microbiology laboratories but should be done only in
selected reference or research settings. Therefore, at present
the laboratory cannot help us to determine which drug should
be used in a specific patient. This also accounts for the fact that
minimal fungicidal concentrations and MICs for fungal isolates
are not used commonly in the neonatal setting, indicating that
at present the minimal fungicidal concentration and MIC have
no value as clinical tools.
In our introduction we stated that amphotericin B with or
without flucytosine was still the treatment of choice for new-
borns with systemic candidiasis. On the basis of the informa-
tion in the literature presented here, amphotericin B remains
the drug of choice for the treatment of systemic candidiasis,
despite the need for prolonged intravenous cannulation and
the potential for serious toxicity. However, newborns on am-
photericin B therapy should concurrently receive recombinant
erythropoietin to overcome the amphotericin B-induced inhi-
bition of erythropoietin production. We recommend a starting
dose of 0.25 to 0.5 mg/kg and, subsequently, a rapid increase of
0.25 to 0.5 mg/kg every 12 to 24 h until the upper limit of 1.0
to 1.5 mg/kg has been reached. Careful monitoring should be
performed, as indicated above. We do not recommend the use
of flucytosine because there are no clinical data on the efficacy
of flucytosine alone or in combination with amphotericin B for
the treatment of systemic candidiasis, and there is a rapid
emergence of resistant Candida strains after flucytosine treat-
ment.
What is the potential role of the new azole drugs (ketocon-
azole, fluconazole, and itraconazole)? Among these three, flu-
conazole has the most attractive profile, including the capacity
to produce high concentrations in cerebrospinal fluid and good
oral absorption unaltered by the presence of food or gastric
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acidity. A potential disadvantage is the emergence of resis-
tance. Ketoconazole is less well tolerated than either flucon-
azole or itraconazole and is associated with more clinically
important toxic effects, including hepatitis and inhibition of
steroid hormone synthesis. However, ketoconazole is much
cheaper than fluconazole and itraconazole. Itraconazole has
fewer potential side effects, but it has unreliable oral absorp-
tion. The use of hydroxypropyl-b-cyclodextrin will probably
overcome this unreliable oral absorption. We like to stress that
in preterm infants the use of all three drugs is limited because
they are often unable to tolerate oral medications.
At present fluconazole, which is available as both an oral and
an intravenous formulation and which has fewer potential side
effects than amphotericin B, must be the antifungal agent that
should be studied in comparative randomized multicenter tri-
als with amphotericin B to obtain insight into the efficacy and
toxicity of this azole drug. We recommend, on the basis of the
experience of Saxen et al. (47), a starting dosage of 6 mg/kg
every 2 days during the first 2 weeks after birth and 6 mg/kg
every day later on.
Careful monitoring as indicated before should be per-
formed.
Finally, in addition to the potential use of these new azole
drugs in the treatment of neonatal systemic candidiasis, the
roles of passive immunotherapy and gamma interferon therapy
should be elucidated.
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